The DOI matches its Crossref record; the references it cites are not checked yet.
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
Open accessAbstract
BACKGROUND Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid. Seladelpar is a potent, selective agonist for the peroxisome proliferator-activated receptor-delta (PPAR-δ), which is implicated in bile acid homoeostasis. This first-in-class study evaluated the anti-cholestatic effects and safety of seladelpar in patients with an inadequate response to ursodeoxycholic acid. METHODS The study was a 12-week, double-blind, placebo-controlled, phase 2 trial of patients with alkaline phosphatase of at least 1·67 times the upper limit of normal (ULN) despite treatment with ursodeoxycholic acid. Patients, recruited at 29 sites in North America and Europe, were randomly assigned to placebo, seladelpar 50 mg/day, or seladelpar 200 mg/day while ursodeoxycholic acid was continued. Randomisation was done centrally (1:1:1) by a computerised system using an interactive voice-web response system with a block size of three. Randomisation was stratified by region (North America and Europe). The primary outcome was the percentage change from baseline in alkaline phosphatase over 12 weeks, analysed in the modified intention-to-treat (ITT) population (any randomised patient who received at least one dose of medication and had at least one post-baseline alkaline phosphatase evaluation). This study is registered with ClinicalTrials.gov (NCT02609048) and the EU Clinical Trials Registry (EudraCT2015-002698-39). FINDINGS Between Nov 4, 2015, and May 26, 2016, 70 patients were screened at 29 sites in North America and Europe. During recruitment, three patients treated with seladelpar developed fully reversible, asymptomatic grade 3 alanine aminotransferase increases (one on 50 mg, two on 200 mg), ranging from just over five to 20 times the ULN; as a result, the study was terminated after 41 patients were randomly assigned. The modified ITT population consisted of 12 patients in the placebo group, 13 in the seladelpar 50 mg group, and 10 in the seladelpar 200 mg group. Mean changes from baseline in alkaline phosphatase were -2% (SD 16) in the placebo group, -53% (14) in the seladelpar 50 mg group, and -63% (8) in the seladelpar 200 mg group. Changes in both seladelpar groups versus placebo were significant (p<0·0001 for both groups vs placebo), with no significant difference between the two seladelpar groups (p=0·1729). All five patients who received seladelpar for 12 weeks had normal alkaline phosphatase values at the end of treatment, based on a central laboratory ULN for alkaline phosphatase of 116 U/L. The most frequently reported adverse events were pruritus (16%; one patient on placebo, four on seladelpar 50 mg, and one on seladelpar 200 mg), nausea (13%; one patient on placebo, three on seladelpar 50 mg, and one on seladelpar 200 mg), diarrhoea (10%; two patients on placebo, one on seladelpar 50 mg, and one on seladelpar 200 mg), dyspepsia (8%; two patients on seladelpar 50 mg and one on seladelpar 200 mg), muscle spasms (8%; three patients on seladelpar 200 mg), myalgia (8%; one patient on placebo and two on seladelpar 200 mg), and dizziness (8%; one patient on placebo and two on seladelpar 50 mg). INTERPRETATION Seladelpar normalised alkaline phosphatase levels in patients who completed 12 weeks of treatment. However, treatment was associated with grade 3 increases in aminotransferases and the study was stopped early. The effects of seladelpar should be explored at lower doses. FUNDING CymaBay Therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, it has anti-inflammatory effects on hepatic macrophages and stellate cells, which in turn reduces pro-inflammatory cytokines and fibrogenic activity [44,45,46].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [44]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“seladelpar, a selective PPAR-δ agonist, has recently been shown to improve measures of cholestasis in patients with primary biliary cholangitis.36”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [36]
In the citing paper
“Seladelpar: PBC (phase 2)160: 12 weeks of seladelpar treatment improved ALP in patients with PBC with inadequate response to UDCA (normalisation in five patients treated for full 12 weeks), but three patients developed fully reversible, asymptomatic grade 3 ALT increases (one on 50 mg, two on 200 mg), study was terminated after 41 patients were randomised.”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [160]
In the citing paper
“New therapies, such as agonists of peroxisome proliferator‐activated receptors, reduce ALP levels but are associated with elevated transaminase concentrations or creatinine levels.9”
From NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 46 · Cited by 191
Metadata
- Authors
- Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., Sheridan, D., Wörns, M.-A., Clark, V., Corless, L., Hartmann, H., Jonas, M. E., Kremer, A. E., Mells, G. F., Buggisch, P., Freilich, B. L., Levy, C., Vierling, J. M., Bernstein, D. E., Hartleb, M., Janczewska, E., Rochling, F., Shah, H., Shiffman, M. L., Smith, J. H., Choi, Y.-J., Steinberg, A., Varga, M., Chera, H., Martin, R., McWherter, C. A., & Hirschfield, G. M.
- Affiliations
- Newcastle University (GB)
- CymaBay Therapeutics (United States) (US)
- University of Calgary (CA)
- University of California, Davis (US)
- Saint Louis University Hospital (US)
- Atlanta Gastroenterology Associates (US)
- Henry Ford Health (US)
- Icahn School of Medicine at Mount Sinai (US)
- Plymouth Hospital (GB)
- Johannes Gutenberg University Mainz (DE)
- University of Florida (US)
- Ohio Gastroenterology and Liver Institute (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Asklepios Klinik St. Georg (DE)
- Kansas City Research Institute (US)
- University of Miami (US)
- Baylor College of Medicine (US)
- North Shore University Hospital (US)
- Medical University of Silesia (PL)
- University of Nebraska Medical Center (US)
- University Health Network (CA)
- Digestive & Liver Disease Specialists (US)
- NIHR Birmingham Biomedical Research Centre (GB)
- Corresponding author
- Boudes, Pol F
- ORCID
- Jones, David
- Boudes, Pol F
- Swain, Mark G
- Bowlus, Christopher L
- Gordon, Stuart C
- Odin, Joseph A
- Sheridan, David
- Clark, Virginia
- Jonas, Mark E
- Kremer, Andreas E
- Mells, George F
- Buggisch, Peter
- Levy, Cynthia
- Vierling, John M
- Hartleb, Marek
- Janczewska, Ewa
- Rochling, Fedja
- Shah, Hemant
- Shiffman, Mitchell L
- Choi, Yun-Jung
- Steinberg, Alexandra
- Martin, Robert
- McWherter, Charles A
- Hirschfield, Gideon M
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 2
- Issue
- 10
- Pages
- 716-726
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W2749610744
- Semantic Scholar
- 80c393fc8d60cb6ecdddbcff05ebc69755aad1c3
- Cited by
- 191
- References
- 46
- Citations by year
- 2026: 13 · 2025: 34 · 2024: 25 · 2023: 17 · 2022: 21 · 2021: 19 · 2020: 20 · 2019: 23 · 2018: 16 · 2017: 3
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- PEARL (University of Plymouth) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- seladelpar, PPARδ agonist, primary biliary cirrhosis, alkaline phosphatase, bile acid homeostasis, alanine aminotransferase elevation, drug safety, treatment discontinuation
- MeSH terms
- Acetates, Adult, Aged, Alanine Transaminase, Cholangitis, Diarrhea, Double-Blind Method, Drug Administration Schedule, Female, Humans, Liver, Male, Middle Aged, Nausea, Pruritus, Triazoles, Ursodeoxycholic Acid, Treatment Outcome, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. https://app.cochat.ai/papers/10.1016/s2468-1253(17)30246-7
- The paper
- Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., Sheridan, D., Wörns, M.-A., Clark, V., Corless, L., Hartmann, H., Jonas, M. E., Kremer, A. E., Mells, G. F., Buggisch, P., . . . Hirschfield, G. M. (2017). Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(17)30246-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.